FDA limits research of former AHA president for submitting false informationBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7377.1377/a (Published 14 December 2002) Cite this as: BMJ 2002;325:1377
- Janice Hopkins Tanne
- New York
Just days before he completed his year as president of the American Heart Association on 30 June, Dr David Faxon signed a consent agreement with the Food and Drug Administration limiting his clinical research.
On 19 June 2002 Dr Faxon agreed that for three years he would not be the principal investigator for more than two FDA regulated clinical investigations at any one time, and that he would not be the principal clinical investigator for a study that enrolled more than 25 subjects. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial